Identification

Name
Nylidrin
Accession Number
DB06152
Type
Small Molecule
Groups
Approved
Description

Nylidrin, also known as buphenine belongs to the category of drugs called vasodilators, which relax blood vessels and increase blood flow. Nylidrin is a peripheral vasodilator. Some studies show the evidence of improving cognitive impairment in selected individuals, such as geriatric patients with mild to moderate symptoms of cognitive, emotional and physical impairment [4].

Nylidrin is utilized to treat several disorders that may benefit from increased blood flow (for example, certain mental disorders, blood vessel disease due to diabetes, frostbite, night leg cramps, and certain types of ulcers). This medication works by dilating (widening) blood vessels to help increase blood flow (improving circulation) throughout the body, including the extremities and central nervous system. This effect may help to improve memory/judgment, improve walking ability, and support the healing of frostbite/ulcers [6].

FDA has considered nylidrin as "lacking substantial evidence of effectiveness" in cerebral ischemia, cerebral arteriosclerosis, and other cerebral circulatory insufficiencies. Therefore, the FDA has withdrawn nylidrin from the U.S. market [9].

Structure
Thumb
Synonyms
  • Bufenina
  • Buphenin
  • Buphenine
  • Bupheninum
External IDs
CS 6712 / SKF 1700-A
Product Ingredients
IngredientUNIICASInChI Key
Nylidrin hydrochlorideEC69E3PW7E849-55-8CLJHABUMMDMAFA-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Arlidin Forte Tab 12mgTablet12 mgOralAventis Pharma Ltd.1974-12-312003-07-22Canada
Arlidin Tablets 6mgTablet6 mgOralErfa Canada 2012 Inc1955-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PMS-nylidrin Tab 6mgTablet6 mgOralPharmascience Inc1983-12-312016-10-28Canada
International/Other Brands
Arbid / Arlidin
Categories
UNII
695DKH33EI
CAS number
447-41-6
Weight
Average: 299.414
Monoisotopic: 299.188529049
Chemical Formula
C19H25NO2
InChI Key
PTGXAUBQBSGPKF-UHFFFAOYSA-N
InChI
InChI=1S/C19H25NO2/c1-14(8-9-16-6-4-3-5-7-16)20-15(2)19(22)17-10-12-18(21)13-11-17/h3-7,10-15,19-22H,8-9H2,1-2H3
IUPAC Name
4-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]propyl}phenol
SMILES
CC(CCC1=CC=CC=C1)NC(C)C(O)C1=CC=C(O)C=C1

Pharmacology

Indication

Nylidrin is mainly indicated in conditions like arteriosclerosis, cerebrovascular disease, peripheral vascular disease, Raynaud's disease, thrombo-angitis obliterans, and thrombophlebitis [8]. It may sometimes be used in the treatment of peripheral vascular disorders in addition premature labor (however, the drug is not approved for premature labor)[2].

Pharmacodynamics

Nylidrin hydrochloride acts mainly by beta-receptor stimulation [1], [15]. Beta stimulation with nylidrin has been studied and confirmed in a variety of isolated tissues from rabbits, guinea pigs, as well as dogs. This drug has been shown to dilate arterioles in skeletal muscle and to increase cardiac output in the anesthetized dog and cat as well as the unanesthetized man. An increase in cerebral blood flow and a decrease in vascular resistance has also been reported. The result of this combination of mechanisms is an improved blood supply to ischemic tissues, with minimal change in blood pressure (generally) [16].

Nylidrin causes peripheral vasodilation, a positive inotropic effect, and an increased volume of gastric acid. [2], [4]. According to one study, there are two primary effects of this agent following the intra‐arterial route of administration: one, to decrease total peripheral resistance; and two, a direct effect on the heart tissue to increase cardiac output [15]. It also acts directly on the arteries and arterioles of the skeletal muscles. Additionally, it suppresses uterine contractility thereby preventing or halting premature labor [11].

Mechanism of action

This drug is classified as a beta receptor agonist [7].The β2-adrenergic receptor belongs to the widely expressed 7-transmembrane receptors superfamily, which signals through heterotrimeric G-proteins. They are frequently referred to as G-protein-coupled receptors because they accomplish signal transduction to the interior of the cell by interactions with guanine nucleotide regulatory binding proteins. The receptor-coupled G-proteins work as “molecular switches” which alternate from an inactive guanosine-diphosphate to an active guanosine-triphosphate (GTP) state, which then act to modulate all downstream cell processes. Signaling by various hormones and neurotransmitters, as well as photons and odors, follows the same general pathway, (i.e., by binding of an extracellular ligand to the receptor, which then interacts with the membrane-bound G-protein). This complex, often referred to as the ternary complex, then acts through the activated G-protein to regulate an effector, such as adenylyl cyclase, phospholipase C, or ion channels [14].

The main effects of Nylidrin may be divided into 3 categories:

Blood vessels

Vascular smooth muscle has β2-adrenoceptors that have a high binding affinity for circulating epinephrine and a lower affinity to norepinephrine released by sympathetic adrenergic nerves [16]. When nylidrin binds to the beta-adrenergic receptors, it prevents the binding of epinephrine, leading to decreased blood vessel contractility as epinephrine is unable to bind [18].

Heart:

Increased intracellular cAMP by beta-2-agonists inhibits myosin light chain kinase, leading to relaxation These receptors, like the receptors in the heart, are coupled to a Gs-protein, which acts stimulate the formation of cAMP. Although increased cAMP increases cardiac myocyte contraction, in vascular smooth muscle, an increase in cAMP causes smooth muscle relaxation. The reason for this is the fact that cAMP inhibits myosin light chain kinase that is responsible for phosphorylating smooth muscle myosin. Increases in intracellular cAMP caused by β2-agonists inhibit myosin light chain kinase thereby producing less contractile force (i.e., promoting relaxation) [16].

Other tissues

Activation of β2-adrenoceptors in the lungs causes bronchodilation. β2-adrenoceptor activation leads to hepatic glycogenolysis and the pancreatic secretion of glucagon, increasing plasma glucose concentrations. β1-adrenoceptor stimulation in the kidneys promotes the release of renin, stimulating the production of angiotensin II and the subsequent release of aldosterone by the adrenal cortex [16].

TargetActionsOrganism
UVoltage-dependent T-type calcium channel subunit alpha-1I
antagonist
agonist
Human
AInterferon alpha/beta receptor 2
agonist
Human
Absorption

Readily absorbed from the gastrointestinal tract [4].

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

Duration of action is 10h [9].

Clearance
Not Available
Toxicity

Adverse effects of oral sympathomimetics, such as Nylidrin, are common. The most frequent effects are hypertension, palpitations, nausea, anxiety, mydriasis, and restlessness/agitation [9].

Large overdoses and severe toxicity may lead to seizures, hallucinations, agitated delirium, and tachydysrhythmias including supraventricular tachycardia and ventricular tachycardia. Vasospasm can lead to myocardial ischemia focal cerebrovascular deficits. Severe hypertension may also result in intracranial hemorrhage or renal insufficiency. Reflex bradycardia because of significant hypertension is possible. Prolonged agitation can lead to rhabdomyolysis and hyperthermia [9].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when Nylidrin is combined with 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Nylidrin is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3-isobutyl-1-methyl-7H-xanthineThe risk or severity of adverse effects can be increased when Nylidrin is combined with 3-isobutyl-1-methyl-7H-xanthine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when Nylidrin is combined with 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when Nylidrin is combined with 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
6-O-benzylguanineThe risk or severity of adverse effects can be increased when Nylidrin is combined with 6-O-benzylguanine.Investigational
7-DeazaguanineThe risk or severity of adverse effects can be increased when Nylidrin is combined with 7-Deazaguanine.Experimental
7,9-DimethylguanineThe risk or severity of adverse effects can be increased when Nylidrin is combined with 7,9-Dimethylguanine.Experimental
8-azaguanineThe risk or severity of adverse effects can be increased when Nylidrin is combined with 8-azaguanine.Experimental
8-chlorotheophyllineThe risk or severity of adverse effects can be increased when Nylidrin is combined with 8-chlorotheophylline.Approved
9-DeazaguanineThe risk or severity of adverse effects can be increased when Nylidrin is combined with 9-Deazaguanine.Experimental
9-MethylguanineThe risk or severity of adverse effects can be increased when Nylidrin is combined with 9-Methylguanine.Experimental
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Nylidrin.Investigational
AcebutololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Acebutolol.Approved, Investigational
AcefyllineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Acefylline.Experimental
AcepromazineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Acepromazine.Approved, Vet Approved
AcyclovirThe risk or severity of adverse effects can be increased when Nylidrin is combined with Acyclovir.Approved
Ajulemic acidThe risk or severity of Tachycardia can be increased when Ajulemic acid is combined with Nylidrin.Investigational
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Nylidrin.Investigational
AlcuroniumNylidrin may increase the neuromuscular blocking activities of Alcuronium.Experimental
AlfuzosinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Alfuzosin.Approved, Investigational
AlprenololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Alprenolol.Approved, Withdrawn
AmineptineThe risk or severity of hypertension can be increased when Amineptine is combined with Nylidrin.Illicit, Withdrawn
AmiodaroneThe metabolism of Nylidrin can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Amitriptyline.Approved
AmitriptylinoxideThe risk or severity of hypertension can be increased when Amitriptylinoxide is combined with Nylidrin.Approved, Investigational
AmobarbitalThe metabolism of Nylidrin can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Amoxapine.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Nylidrin.Approved, Illicit, Investigational
Amphotericin BNylidrin may decrease the nephrotoxic activities of Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Nylidrin can be decreased when combined with Amprenavir.Approved, Investigational
AnisodamineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Anisodamine.Investigational
ApalutamideThe serum concentration of Nylidrin can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Nylidrin can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Aripiprazole.Approved, Investigational
Aripiprazole lauroxilThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Aripiprazole lauroxil.Approved, Investigational
ArotinololThe risk or severity of hypotension can be increased when Arotinolol is combined with Nylidrin.Investigational
AsenapineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Asenapine.Approved
AtazanavirThe metabolism of Nylidrin can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Atenolol.Approved
AtomoxetineThe risk or severity of hypertension can be increased when Atomoxetine is combined with Nylidrin.Approved
AtracuriumNylidrin may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateNylidrin may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzathioprineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Azathioprine.Approved
BamifyllineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Bamifylline.Experimental
BarbexacloneThe metabolism of Nylidrin can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Nylidrin can be increased when combined with Barbital.Illicit
BefunololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Befunolol.Experimental
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Nylidrin.Approved, Illicit
Benzylpenicilloyl PolylysineNylidrin may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetaxololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Betaxolol.Approved, Investigational
BevantololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Bevantolol.Approved
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Nylidrin.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Nylidrin.Approved
BisoprololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Bisoprolol.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Nylidrin.Approved
BoceprevirThe metabolism of Nylidrin can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Bopindolol.Approved
BosentanThe serum concentration of Nylidrin can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Brexpiprazole.Approved, Investigational
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved, Investigational
BromotheophyllineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Bromotheophylline.Approved
BucindololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Bucindolol.Investigational
BufuralolThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Bufuralol.Experimental, Investigational
BufyllineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Bufylline.Experimental
BunazosinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Bunazosin.Investigational
BupranololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Bupranolol.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Nylidrin.Approved
ButriptylineThe risk or severity of hypertension can be increased when Butriptyline is combined with Nylidrin.Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved
CafedrineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Cafedrine.Investigational
CaffeineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Caffeine.Approved
Calcium AcetateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium Phosphate.Approved
CannabidiolThe risk or severity of Tachycardia can be increased when Cannabidiol is combined with Nylidrin.Approved, Investigational
CarbamazepineThe metabolism of Nylidrin can be increased when combined with Carbamazepine.Approved, Investigational
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Nylidrin.Approved, Investigational
CarteololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Carteolol.Approved
CarvedilolThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Carvedilol.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Nylidrin.Approved, Investigational, Nutraceutical, Vet Approved
CeliprololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Nylidrin can be increased when it is combined with Ceritinib.Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Nylidrin.Illicit, Withdrawn
ChlorpromazineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Chlorpromazine.Approved, Investigational, Vet Approved
CimetidineThe serum concentration of Nylidrin can be increased when it is combined with Cimetidine.Approved, Investigational
CisatracuriumNylidrin may increase the neuromuscular blocking activities of Cisatracurium.Approved
ClarithromycinThe metabolism of Nylidrin can be decreased when combined with Clarithromycin.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Nylidrin.Approved, Investigational, Vet Approved
ClomipramineThe risk or severity of hypertension can be increased when Clomipramine is combined with Nylidrin.Approved, Investigational, Vet Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nylidrin.Approved
CloranololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Cloranolol.Experimental
ClotrimazoleThe metabolism of Nylidrin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Clozapine.Approved
CobicistatThe metabolism of Nylidrin can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Nylidrin.Approved, Investigational
CP-945598The risk or severity of Tachycardia can be increased when CP-945598 is combined with Nylidrin.Investigational
CrizotinibThe metabolism of Nylidrin can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Nylidrin can be decreased when combined with Curcumin.Approved, Investigational
CyclobenzaprineThe risk or severity of hypertension can be increased when Cyclobenzaprine is combined with Nylidrin.Approved
CyclosporineThe metabolism of Nylidrin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Nylidrin can be decreased when it is combined with Dabrafenib.Approved, Investigational
DanazolThe metabolism of Nylidrin can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Nylidrin.Approved, Investigational, Withdrawn
DapiprazoleThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Dapiprazole.Approved
DarunavirThe metabolism of Nylidrin can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Nylidrin can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Nylidrin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Nylidrin can be decreased when combined with Delavirdine.Approved
DesipramineThe risk or severity of hypertension can be increased when Desipramine is combined with Nylidrin.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Nylidrin.Approved, Investigational
DexamethasoneThe serum concentration of Nylidrin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextroamphetamineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Dextroamphetamine.Approved, Illicit
DibenzepinThe risk or severity of hypertension can be increased when Dibenzepin is combined with Nylidrin.Experimental
DiethylpropionThe risk or severity of adverse effects can be increased when Nylidrin is combined with Diethylpropion.Approved, Illicit
DihydroergocornineDihydroergocornine may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved
DihydroergocristineDihydroergocristine may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved, Experimental
DihydroergocryptineDihydroergocryptine may increase the hypertensive and vasoconstricting activities of Nylidrin.Experimental
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved, Investigational
DiltiazemThe metabolism of Nylidrin can be decreased when combined with Diltiazem.Approved, Investigational
DimetacrineThe risk or severity of hypertension can be increased when Dimetacrine is combined with Nylidrin.Approved, Withdrawn
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Nylidrin.Approved
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Nylidrin.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Nylidrin.Approved
DosulepinThe risk or severity of hypertension can be increased when Dosulepin is combined with Nylidrin.Approved
DoxacuriumNylidrin may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Doxazosin.Approved
DoxepinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Doxepin.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Doxofylline.Approved, Investigational
DoxycyclineThe metabolism of Nylidrin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe risk or severity of Tachycardia can be increased when Dronabinol is combined with Nylidrin.Approved, Illicit
DronedaroneThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Dronedarone.Approved
DroperidolThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Droperidol.Approved, Vet Approved
DuloxetineDuloxetine may increase the tachycardic activities of Nylidrin.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Nylidrin.Approved
EfavirenzThe serum concentration of Nylidrin can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Nylidrin.Approved
EntecavirThe risk or severity of adverse effects can be increased when Nylidrin is combined with Entecavir.Approved, Investigational
EnzalutamideThe serum concentration of Nylidrin can be decreased when it is combined with Enzalutamide.Approved
EpanololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Epanolol.Experimental
EphedrineThe risk or severity of adverse effects can be increased when Ephedrine is combined with Nylidrin.Approved
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Nylidrin.Approved, Vet Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved
ErythromycinThe metabolism of Nylidrin can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Esatenolol.Experimental
EsmololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Esmolol.Approved
EtamiphyllineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Etamiphylline.Experimental
EtilefrineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Etilefrine.Withdrawn
EtravirineThe serum concentration of Nylidrin can be decreased when it is combined with Etravirine.Approved
FenethyllineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Fenethylline.Approved
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Nylidrin.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Nylidrin is combined with Fenozolone.Experimental
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Nylidrin.Experimental
FluconazoleThe metabolism of Nylidrin can be decreased when combined with Fluconazole.Approved, Investigational
FlupentixolThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Flupentixol.Approved, Investigational, Withdrawn
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Nylidrin.Experimental
FluvoxamineThe metabolism of Nylidrin can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Nylidrin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Nylidrin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Nylidrin.Approved, Investigational
FurafyllineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Furafylline.Experimental
Fusidic AcidThe serum concentration of Nylidrin can be increased when it is combined with Fusidic Acid.Approved, Investigational
GallamineNylidrin may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideNylidrin may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GanciclovirThe risk or severity of adverse effects can be increased when Nylidrin is combined with Ganciclovir.Approved, Investigational
GepefrineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Gepefrine.Experimental
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Nylidrin.Approved, Investigational
GuanineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Guanine.Experimental
GW842166The risk or severity of Tachycardia can be increased when GW842166 is combined with Nylidrin.Investigational
HexobarbitalThe metabolism of Nylidrin can be increased when combined with Hexobarbital.Approved
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Hydroxyamphetamine.Approved
HypoxanthineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Hypoxanthine.Experimental
IbipinabantThe risk or severity of Tachycardia can be increased when Ibipinabant is combined with Nylidrin.Investigational
IdelalisibThe metabolism of Nylidrin can be decreased when combined with Idelalisib.Approved
IloperidoneThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Iloperidone.Approved
ImatinibThe metabolism of Nylidrin can be decreased when combined with Imatinib.Approved
ImipramineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Imipramine.Approved
Imipramine oxideThe risk or severity of hypertension can be increased when Imipramine oxide is combined with Nylidrin.Experimental
IndenololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Indenolol.Withdrawn
IndinavirThe metabolism of Nylidrin can be decreased when combined with Indinavir.Approved
IndoraminThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Indoramin.Withdrawn
IobenguaneNylidrin can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Iofetamine I-123The risk or severity of adverse effects can be increased when Nylidrin is combined with Iofetamine I-123.Approved
IprindoleThe risk or severity of hypertension can be increased when Iprindole is combined with Nylidrin.Experimental
IsavuconazoleThe serum concentration of Nylidrin can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Nylidrin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Nylidrin.Approved
IsoniazidThe metabolism of Nylidrin can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Nylidrin.Approved, Investigational
IsoxsuprineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Isoxsuprine.Approved, Withdrawn
ItraconazoleThe metabolism of Nylidrin can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Nylidrin can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Nylidrin can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Labetalol.Approved
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Nylidrin.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Nylidrin.Approved
LandiololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Landiolol.Investigational
LevobetaxololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Levobetaxolol.Approved, Investigational
LevobunololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Levobunolol.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Nylidrin.Approved, Investigational
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Nylidrin.Approved
LinezolidThe risk or severity of hypertension can be increased when Linezolid is combined with Nylidrin.Approved, Investigational
LisdexamfetamineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Lisdexamfetamine.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Lisofylline.Investigational
LisurideLisuride may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved, Investigational
LobucavirThe risk or severity of adverse effects can be increased when Nylidrin is combined with Lobucavir.Investigational
LofepramineThe risk or severity of hypertension can be increased when Lofepramine is combined with Nylidrin.Experimental
LopinavirThe metabolism of Nylidrin can be decreased when combined with Lopinavir.Approved
LorpiprazoleThe serum concentration of Nylidrin can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Nylidrin can be decreased when combined with Lovastatin.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Nylidrin.Approved, Investigational
LuliconazoleThe serum concentration of Nylidrin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Nylidrin can be increased when combined with Lumacaftor.Approved
Lysergic Acid DiethylamideLysergic Acid Diethylamide may increase the hypertensive and vasoconstricting activities of Nylidrin.Illicit, Investigational, Withdrawn
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Nylidrin.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Nylidrin.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Nylidrin is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Nylidrin is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Nylidrin.Experimental
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Nylidrin is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Nylidrin is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Nylidrin.Approved, Investigational
MefenorexThe risk or severity of adverse effects can be increased when Nylidrin is combined with Mefenorex.Experimental
MelitracenThe risk or severity of hypertension can be increased when Melitracen is combined with Nylidrin.Experimental, Investigational
MephedroneThe risk or severity of adverse effects can be increased when Nylidrin is combined with Mephedrone.Investigational
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Nylidrin.Approved
MepindololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Mepindolol.Experimental
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Nylidrin.Approved, Investigational
MetergolineMetergoline may increase the hypertensive and vasoconstricting activities of Nylidrin.Experimental
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Nylidrin.Approved, Illicit
MethohexitalThe metabolism of Nylidrin can be increased when combined with Methohexital.Approved
MethotrimeprazineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Nylidrin.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Methoxyphenamine.Experimental
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Nylidrin.Approved
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved
MethylphenobarbitalThe metabolism of Nylidrin can be increased when combined with Methylphenobarbital.Approved
MethysergideMethysergide may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved
MetipranololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Metipranolol.Approved
MetocurineNylidrin may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideNylidrin may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetoprololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Metoprolol.Approved, Investigational
MibefradilThe metabolism of Nylidrin can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Nylidrin can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Nylidrin.Approved
MidomafetamineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Midomafetamine.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Nylidrin can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the tachycardic activities of Nylidrin.Approved, Investigational
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Nylidrin.Approved, Vet Approved
MitotaneThe serum concentration of Nylidrin can be decreased when it is combined with Mitotane.Approved
MivacuriumNylidrin may increase the neuromuscular blocking activities of Mivacurium.Approved
MMDAThe risk or severity of adverse effects can be increased when Nylidrin is combined with MMDA.Experimental, Illicit
ModafinilThe serum concentration of Nylidrin can be decreased when it is combined with Modafinil.Approved, Investigational
NabiloneThe risk or severity of Tachycardia can be increased when Nabilone is combined with Nylidrin.Approved, Investigational
NabiximolsThe risk or severity of Tachycardia can be increased when Nabiximols is combined with Nylidrin.Approved, Investigational
NadololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Nadolol.Approved
NafcillinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Nafcillin.Approved, Investigational
NaloxoneThe metabolism of Nylidrin can be decreased when combined with Naloxone.Approved, Vet Approved
NebivololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Nebivolol.Approved, Investigational
NefazodoneThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Nylidrin can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Nylidrin can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Nylidrin can be increased when combined with Nevirapine.Approved
NicardipineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Nicardipine.Approved, Investigational
NicergolineNicergoline may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved, Investigational
NiguldipineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Niguldipine.Experimental
NilotinibThe metabolism of Nylidrin can be decreased when combined with Nilotinib.Approved, Investigational
NitroprussideNylidrin may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Nylidrin.Approved
NortriptylineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Nortriptyline.Approved
OlanzapineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Nylidrin can be decreased when combined with Olaparib.Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Nylidrin.Experimental
OpipramolThe risk or severity of hypertension can be increased when Opipramol is combined with Nylidrin.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Nylidrin.Approved
OsimertinibThe serum concentration of Nylidrin can be increased when it is combined with Osimertinib.Approved
OxaprotilineThe risk or severity of hypertension can be increased when Oxaprotiline is combined with Nylidrin.Experimental
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Nylidrin.Approved
OxprenololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Oxprenolol.Approved
OxtriphyllineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Oxtriphylline.Approved
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Nylidrin.Approved, Investigational
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Nylidrin.Investigational, Withdrawn
PalbociclibThe serum concentration of Nylidrin can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Paliperidone.Approved
PalmidrolThe risk or severity of Tachycardia can be increased when Palmidrol is combined with Nylidrin.Experimental, Nutraceutical
PancuroniumNylidrin may increase the neuromuscular blocking activities of Pancuronium.Approved
Patent BlueThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Patent Blue.Approved
PeldesineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Peldesine.Experimental, Investigational
PemetrexedThe risk or severity of adverse effects can be increased when Nylidrin is combined with Pemetrexed.Approved, Investigational
PenbutololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Penbutolol.Approved, Investigational
PenciclovirThe risk or severity of adverse effects can be increased when Nylidrin is combined with Penciclovir.Approved
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Nylidrin.Experimental
PentifyllineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Pentifylline.Experimental
PentobarbitalThe metabolism of Nylidrin can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Pentoxifylline.Approved, Investigational
PergolidePergolide may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved, Investigational, Vet Approved, Withdrawn
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Nylidrin.Approved, Illicit
PhenobarbitalThe metabolism of Nylidrin can be increased when combined with Phenobarbital.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Nylidrin.Approved, Withdrawn
PhenoxybenzamineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Phenoxybenzamine.Approved
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Nylidrin.Approved, Illicit
PhentolamineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Phentolamine.Approved
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Nylidrin.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Nylidrin.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nylidrin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Nylidrin.Approved
PindololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Pindolol.Approved, Investigational
PipecuroniumNylidrin may increase the neuromuscular blocking activities of Pipecuronium.Approved
PitolisantThe serum concentration of Nylidrin can be decreased when it is combined with Pitolisant.Approved, Investigational
PizotifenThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Pizotifen.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Nylidrin.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Nylidrin.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Nylidrin.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Nylidrin.Approved, Vet Approved
PosaconazoleThe metabolism of Nylidrin can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Nylidrin.Approved, Investigational
PractololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Practolol.Approved
PrazosinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Prazosin.Approved
PrenalterolThe risk or severity of adverse effects can be increased when Nylidrin is combined with Prenalterol.Experimental
PrimidoneThe metabolism of Nylidrin can be increased when combined with Primidone.Approved, Vet Approved
ProcaterolThe risk or severity of adverse effects can be increased when Procaterol is combined with Nylidrin.Approved, Investigational
PromazineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Promazine.Approved, Vet Approved
PropafenoneThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Propafenone.Approved
PropentofyllineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Propentofylline.Investigational
PropericiazineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Propericiazine.Approved, Investigational
PropiomazineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Propiomazine.Approved
PropiverineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Propiverine.Approved, Investigational
PropranololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Propranolol.Approved, Investigational
ProtriptylineThe risk or severity of hypertension can be increased when Protriptyline is combined with Nylidrin.Approved
ProxyphyllineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Proxyphylline.Experimental
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Nylidrin.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Pseudoephedrine.Approved
QuetiapineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Quetiapine.Approved
QuinidineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Quinidine.Approved, Investigational
QuinineThe metabolism of Nylidrin can be increased when combined with Quinine.Approved
QuinupramineThe risk or severity of hypertension can be increased when Quinupramine is combined with Nylidrin.Experimental
RacepinephrineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Racepinephrine.Approved
RapacuroniumNylidrin may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Nylidrin.Investigational
RifampicinThe metabolism of Nylidrin can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Nylidrin can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Nylidrin can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Nylidrin can be increased when combined with Rifaximin.Approved, Investigational
RimexoloneThe metabolism of Nylidrin can be increased when combined with Rimexolone.Approved
RimonabantThe risk or severity of Tachycardia can be increased when Rimonabant is combined with Nylidrin.Approved, Investigational
RisperidoneThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Risperidone.Approved, Investigational
RitobegronThe risk or severity of adverse effects can be increased when Nylidrin is combined with Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Nylidrin.Approved, Investigational
RitonavirThe metabolism of Nylidrin can be decreased when combined with Ritonavir.Approved, Investigational
RocuroniumNylidrin may increase the neuromuscular blocking activities of Rocuronium.Approved
SaquinavirThe metabolism of Nylidrin can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Sarilumab.Approved, Investigational
SecobarbitalThe metabolism of Nylidrin can be increased when combined with Secobarbital.Approved, Vet Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Nylidrin.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Nylidrin.Approved, Investigational
SibutramineSibutramine may increase the tachycardic activities of Nylidrin.Approved, Illicit, Investigational, Withdrawn
SilodosinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Silodosin.Approved
SiltuximabThe serum concentration of Nylidrin can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Nylidrin can be increased when it is combined with Simeprevir.Approved
SLV319The risk or severity of Tachycardia can be increased when SLV319 is combined with Nylidrin.Investigational
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Nylidrin.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Nylidrin.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Nylidrin.Approved
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Nylidrin.Approved
SotalolThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Sotalol.Approved
SpironolactoneThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Spironolactone.Approved
St. John's WortThe serum concentration of Nylidrin can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Nylidrin can be increased when it is combined with Stiripentol.Approved
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Nylidrin.Approved
SurinabantThe risk or severity of Tachycardia can be increased when Surinabant is combined with Nylidrin.Investigational
SynephrineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Synephrine.Experimental
TalinololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Talinolol.Investigational
TamsulosinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Tamsulosin.Approved, Investigational
Tedizolid phosphateTedizolid phosphate may increase the hypertensive activities of Nylidrin.Approved
TegaserodThe therapeutic efficacy of Tegaserod can be decreased when used in combination with Nylidrin.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Nylidrin can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Nylidrin can be decreased when combined with Telithromycin.Approved
TerazosinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Terazosin.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Nylidrin.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Nylidrin.Approved
TergurideTerguride may increase the hypertensive and vasoconstricting activities of Nylidrin.Experimental
TertatololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Tertatolol.Experimental
TetryzolineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Tetryzoline.Approved
TheobromineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Theobromine.Approved, Investigational
TheodrenalineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Theodrenaline.Investigational
ThiamylalThe metabolism of Nylidrin can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Nylidrin can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Thioproperazine.Approved
ThioridazineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Thioridazine.Approved, Withdrawn
TianeptineThe risk or severity of hypertension can be increased when Tianeptine is combined with Nylidrin.Approved, Investigational
TimololThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Timolol.Approved
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Nylidrin.Approved
TipranavirThe metabolism of Nylidrin can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Nylidrin can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Tolazoline.Approved, Vet Approved
TramazolineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Tramazoline.Investigational
TrazodoneThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Trazodone.Approved, Investigational
TretoquinolThe risk or severity of adverse effects can be increased when Nylidrin is combined with Tretoquinol.Experimental
TrifluoperazineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Trifluoperazine.Approved, Investigational
TrimazosinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Trimazosin.Experimental
TrimipramineThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Trimipramine.Approved
TroleandomycinThe metabolism of Nylidrin can be decreased when combined with Troleandomycin.Approved
TubocurarineNylidrin may increase the neuromuscular blocking activities of Tubocurarine.Approved
TyramineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Tyramine.Investigational, Nutraceutical
UrapidilThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Urapidil.Investigational
Uric AcidThe risk or severity of adverse effects can be increased when Nylidrin is combined with Uric Acid.Experimental, Investigational
ValaciclovirThe risk or severity of adverse effects can be increased when Nylidrin is combined with Valaciclovir.Approved, Investigational
ValganciclovirThe risk or severity of adverse effects can be increased when Nylidrin is combined with Valganciclovir.Approved, Investigational
ValomaciclovirThe risk or severity of adverse effects can be increased when Nylidrin is combined with Valomaciclovir.Investigational
VecuroniumNylidrin may increase the neuromuscular blocking activities of Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Nylidrin.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Nylidrin.Approved
VerapamilThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Verapamil.Approved
VoriconazoleThe metabolism of Nylidrin can be decreased when combined with Voriconazole.Approved, Investigational
WIN 55212-2The risk or severity of Tachycardia can be increased when WIN 55212-2 is combined with Nylidrin.Experimental
XanthineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Xanthine.Experimental
ZiprasidoneThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Ziprasidone.Approved
ZuclopenthixolThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals.

References

General References
  1. Niemeyer G, Cottier D, Resch H: Effects of buphenine (nylidrin) on the perfused mammalian eye. Graefes Arch Clin Exp Ophthalmol. 1987;225(1):33-8. [PubMed:2883089]
  2. Castren O, Gummerus M, Saarikoski S: Treatment of imminent premature labour. Acta Obstet Gynecol Scand. 1975;54(2):95-100. [PubMed:1094787]
  3. Walter U, Waldmann R, Nieberding M: Intracellular mechanism of action of vasodilators. Eur Heart J. 1988 Jun;9 Suppl H:1-6. [PubMed:3049092]
  4. PubChem, Nylidrin [Link]
  5. Nylidrin (Oral) [Link]
  6. Nylidrin - Oral [Link]
  7. Nylidrin [Link]
  8. Drug monograph [Link]
  9. ToxNet Nylidrin [Link]
  10. Central cardiovascular effects of nylidrin (buphenine) [Link]
  11. Buphenine, MIMS [Link]
  12. Central cardiovascular effects of nylidrin (buphenine). [Link]
  13. Nylidrin [Link]
  14. Beta-Adrenergic Agonists [Link]
  15. Local and systemic hemodynamic effects of nylidrin [Link]
  16. Nylidrin Hydrochloride [Link]
  17. Specific blockade of spasmogens by β‐receptor stimulation with nylidrin and isoprenaline [Link]
  18. NyIidrin HCL: A BETA-SYMPATHETIC STIMULANT IN THE MANAGEMENT OF HAEMORRHAGIC SHOCK [Link]
External Links
PubChem Compound
4567
PubChem Substance
347827757
ChemSpider
4407
ChEBI
91656
ChEMBL
CHEMBL114655
Wikipedia
Nylidrin
ATC Codes
G02CA02 — BuphenineC04AA02 — Buphenine
AHFS Codes
  • 24:12.92 — Miscellaneous Vasodilatating Agents
MSDS
Download (107 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral12 mg
TabletOral6 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)217MSDS
Predicted Properties
PropertyValueSource
Water Solubility0.0204 mg/mLALOGPS
logP2.73ALOGPS
logP3.05ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)9.25ChemAxon
pKa (Strongest Basic)10.11ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area52.49 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity90.06 m3·mol-1ChemAxon
Polarizability34.56 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylpropanes
Direct Parent
Phenylpropanes
Alternative Parents
Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
Substituents
Phenylpropane / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Aralkylamine / 1,2-aminoalcohol / Secondary alcohol / Secondary aliphatic amine / Secondary amine / Hydrocarbon derivative / Organopnictogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1I
Uniprot ID
Q9P0X4
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1I
Molecular Weight
245100.8 Da
References
  1. Central cardiovascular effects of nylidrin (buphenine). [Link]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Type i interferon receptor activity
Specific Function
Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are direc...
Gene Name
IFNAR2
Uniprot ID
P48551
Uniprot Name
Interferon alpha/beta receptor 2
Molecular Weight
57758.24 Da
References
  1. ToxNet Nylidrin [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
O-methyltransferase activity
Specific Function
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOP...
Gene Name
COMT
Uniprot ID
P21964
Uniprot Name
Catechol O-methyltransferase
Molecular Weight
30036.77 Da
References
  1. Kurki T, Schultz E, Linden IB, Ylikorkala O: Catechol-O-methyltransferase activity in red blood cells in threatened preterm labor; effect of indomethacin and nylidrin. Acta Obstet Gynecol Scand. 1991;70(3):187-91. [PubMed:1927294]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Uesawa Y, Takeuchi T, Mohri K: Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. [PubMed:22039822]

Drug created on January 20, 2008 19:19 / Updated on August 13, 2018 10:11